PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers

Key Takeaways

• Cost management remains the primary goal for payers managing specialty drug benefits in 2026
• Coverage strategy for new drugs and indications emerges as the biggest specialty drug management challenge
• Payers are increasing focus on specialty drugs covered under medical benefits as treatment complexity grows

---

DALLAS - Pharmaceutical Strategies Group (PSG), an EPIC company, released its 2026 Trends in Specialty Drug Benefits Report, revealing that cost management continues to dominate payers’ priorities while coverage strategies for new drugs present unprecedented challenges.

The comprehensive report, now in its 13th year and co-sponsored by Genentech, provides critical insights into how healthcare payers navigate the complex landscape of rising specialty drug costs, increasing treatment complexity, and the ongoing struggle to balance affordability with patient access.

Key Findings Shape Industry Strategy

PSG’s research indicates a significant shift in payer attention toward specialty drugs covered under medical benefits, reflecting the evolving nature of specialty therapeutics and their administration requirements. This trend highlights the growing complexity of benefit design as traditional pharmacy and medical benefit boundaries blur.

The identification of coverage strategy development as the primary management challenge signals a maturation in the specialty drug market. While cost containment remains paramount, payers now face the sophisticated task of creating nuanced coverage policies that can adapt to rapidly emerging therapies and expanded indications for existing treatments.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications and Industry Response

The report’s findings carry significant implications for pharmaceutical manufacturers, healthcare providers, and patients. As payers refine their coverage strategies, drug developers may need to adjust their market access approaches, potentially emphasizing real-world evidence and health economic data earlier in the development process.

For healthcare systems, these trends suggest continued evolution in specialty drug management protocols, with increased emphasis on clinical decision support tools and prior authorization processes that can efficiently evaluate new therapeutic options.

The research underscores the specialty pharmaceutical market’s continued growth and complexity, with payers seeking more sophisticated tools to manage both established and emerging therapies while maintaining fiscal responsibility and ensuring appropriate patient access to life-changing treatments.

---

Frequently Asked Questions

What does this mean for patients accessing specialty drugs?

Patients may experience more complex coverage determination processes as payers develop sophisticated strategies for new drugs and indications, potentially requiring additional documentation or prior authorization steps.

How are payers changing their approach to specialty drug management?

Payers are shifting focus toward specialty drugs under medical benefits and developing more nuanced coverage strategies rather than relying solely on cost containment measures.

What challenges do pharmaceutical companies face based on these findings?

Drug manufacturers must adapt their market access strategies to address payers’ evolving coverage policies and demonstrate value through real-world evidence and health economic data.

Related coverage

• NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact
• Regulatory Round-Up: Key Drug Approvals on May 18, 2026
• Regulatory Round-Up: Drug Approvals on April 20, 2026